Is there a future for Trop-2-targeted ADCs in urothelial carcinoma?

The treatment landscape of advanced urothelial carcinoma (UC) has been transformed by the introduction of antibody–drug conjugates (ADCs). Enfortumab vedotin,1 a nectin-4-directed ADC with a monomethyl auristatin E (MMAE) payload, and disitamab vedotin,2 a human epidermal growth factor receptor 2-directed MMAE ADC, have both demonstrated high single-agent response rates in pretreated advanced disease. Combinations of these ADCs with immune checkpoint…